ADAG

$3.91

Post-MarketAs of Mar 17, 8:00 PM UTC

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.91
Potential Upside
5%
Whystock Fair Value$4.11
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$184.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-63.26%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.20

Recent News

MarketBeat
Mar 10, 2026

Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon

Adagene (NASDAQ:ADAG) outlined its clinical and strategic priorities at Leerink Partners’ global healthcare conference, with Chief Strategy Officer Mickael Chane-Du focusing primarily on the company’s lead program, ADG126, and its progress in metastatic microsatellite-stable colorectal cancer (MSS C

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Feb 25, 2026

Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk

Adagene (NASDAQ:ADAG) highlighted updated details around its lead immuno-oncology program, ADG126, during an Oppenheimer discussion featuring Chief Strategy Officer Mickael Chane-Du. The company is developing ADG126 as a “masked” anti-CTLA-4 antibody intended to improve the safety of CTLA-4 blockade

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 16, 2026

Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders

MRNA shares jumped 5.3% as investors rotated into large-cap biotech, betting on its expanding pipeline in volatile trade.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 19, 2026

Penny Stocks To Watch In January 2026

As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past market trends, continue to offer intriguing possibilities for those willing to explore smaller or newer companies at accessible price points. By focusing on solid financials and growth potential, these stocks can present unique opportunities for investors looking to tap into under-the-radar...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Dec 19, 2025

3 Promising Penny Stocks With Market Caps Over $30M

Major stock indexes in the United States have recently experienced a surge, driven by gains in technology shares and positive economic indicators. While the term "penny stocks" might seem outdated, it still refers to shares of smaller or newer companies that can offer significant potential for growth. By focusing on those with solid financial foundations, investors can uncover opportunities that may provide stability and upside potential.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
ADAG Stock Analysis & Real-Time Data | Whystock